logo image
search icon
Beyond the Pill Market

Beyond the Pill Market Size, Share & Trends Analysis Report By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, And Others) And Offerings (Services, Monitoring, Assistance, Information, And Education), By Region, And Segment Forecasts, 2023-2031

Report ID : 1567 | Published : 2023-03-02 | Pages: 180 | Format: PDF/EXCEL

The Global Beyond The Pill Market Size is predicted to register at an 11.34% CAGR during the forecast period for 2023-2031.

Beyond the pill, approaches may include illness and therapy knowledge, diagnosis, therapy implementation, enhancement of pharmaceutical accessibility, and general patient support. Rising prevalence of lifestyle-related ailments such as overeating, stomach ulcers, peptic ulcer disease (GERD), and others, and rise in chronic disorders such as cancer, hypertension, and others are important drivers driving the growth of the beyond the pills market.

Beyond the Pill Market

Furthermore, increasing study and development activities for creating the beyond-the-pill drive market growth. On the other hand, the massive price of orally administered sensors and strong government regulations that govern the expanding use of these devices are expected to restrain market expansion. Additionally, the added benefits of medical technology to diagnose and diagnose disease in a hospital manner while simultaneously classifying gene mutations, extended therapeutic provision, and personalized medicine further enhance the growth prospects of the global beyond-pill market in the upcoming five years.

In the next five years, technological improvements and factors influencing location-based healthcare services, smartphone applications, and remote monitoring devices will significantly impact the global market for alternatives to pills. Health results anticipated from therapeutic or pharmaceutical products can be improved with digital pharmaceutical services or "beyond the pill" services. These offerings are also strengthening the competition. The rise of generics and biosimilars is accompanied by increased competition among global players. 

Recent Developments: 

  • In May 2021, Eli Lilly and Company signed key international partnerships with four businesses – DexCom, Inc., Glooko, Inc., myDiabby Healthcare, and Roche – to enhance connected solutions and expedite diabetes treatment in overseas markets. These companies provide diabetes management systems compatible with Lilly's Tempo PenTM (approved in several worldwide markets) and Tempo Smart ButtonTM (currently in late-stage development) to help individuals with diabetes and healthcare professionals. 

Competitive Landscape:

Some major key players in the Beyond The Pill market are:

  • F. Hoffmann-La Roche AG (Flatiron Health)
  • Otsuka Pharmaceuticals Co., Ltd
  • Amgen, Inc.
  • AstraZeneca Plc
  • Novartis AG
  • Sanofi S.A
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd., 

Market Segmentation:

The beyond-the-pill market is segmented on the therapeutic area and offerings. Based on therapeutic areas, the market is further fragmented into diabetes, oncology, cardiovascular diseases, asthma, and others. The market is bifurcated into services, monitoring, assistance, information, and education based on offerings.

Based On The Therapeutic Area, Oncology Is A Major Contributor To The Beyond-The-Pill Market

The market's leading segment is oncology. The global market is expanding due to the growing burden of cancer across the world due to rising alcohol and tobacco use. 20% of pharmaceutical sales worldwide are accounted for by oncology therapies alone. As a result, the oncology sector attracts investors due to its growing importance and increasing profit potential. The demand for early cancer detection and treatment has increased due to the increasing frequency of numerous chronic diseases.

The Monitoring Segment Witnessed Growth At A Rapid Rate

The monitoring segment grabbed the highest revenue share, and it is anticipated that it will continue to hold that position during the anticipated time. The rising prevalence of diseases such as diabetes, stroke, and renal disease is increasing the need for patient monitoring. Major market participants' tactics for expanding the sector include collaboration, teamwork, innovation, launches, and mergers. Throughout the world, social segregation and quarantining methods were developed during the COVID-19 pandemic. As a result, many people avoided regular visits to the hospital. Many people now require routine home temperature and oxygen level monitoring to maintain track of their health. h. As a result, demanding monitor

The North American Beyond The Pill Market Holds A Significant Regional Revenue Share

The North American beyond the pill market is expected to register the highest market share in revenue shortly. The trend is projected to continue due to many players and increased technology improvements in the region's healthcare industry. The highest market share can be attributable to healthcare expenditure scenarios, FDA and other certifications for pill technology-based products, and increased government and other agency investments. In addition, Asia Pacific is projected to grow rapidly in the global beyond the pill market. This is due to increasing technical improvements in the diagnosis of many cancers.

Global Beyond The Pill Market Report Scope:

Report Attribute

Specifications

Growth rate CAGR

CAGR of 11.34% from 2023 to 2031

Quantitative units

Representation of revenue in US$ Million, and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments covered

Therapeutic Area And Offerings

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

F. Hoffmann-La Roche AG (Flatiron Health), Otsuka Pharmaceuticals Co., Ltd., Amgen, Inc., AstraZeneca Plc., Novartis AG, Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd.

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Beyond the Pill Market Snapshot

Chapter 4. Global Beyond the Pill Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Therapeutic Area:

5.2.1. Diabetes
5.2.2. Oncology
5.2.3. Cardiovascular Diseases
5.2.4. Asthma
5.2.5. Others

Chapter 6. Market Segmentation 2: by Offerings Estimates & Trend Analysis
6.1. by Offerings & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Offerings:

6.2.1. Services
6.2.2. Monitoring
6.2.3. Assistance
6.2.4. Information
6.2.5. Education

Chapter 7. Beyond the Pill Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
7.1.2. North America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Offerings, 2023-2031
7.1.3. North America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

7.2. Europe

7.2.1. Europe Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
7.2.2. Europe Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Offerings, 2023-2031
7.2.3. Europe Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

7.3. Asia Pacific

7.3.1. Asia Pacific Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
7.3.2. Asia Pacific Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Offerings, 2023-2031
7.3.3. Asia Pacific Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

7.4. Latin America

7.4.1. Latin America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
7.4.2. Latin America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Offerings, 2023-2031
7.4.3. Latin America Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
7.5.2. Middle East & Africa Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by Offerings, 2023-2031
7.5.3. Middle East & Africa Beyond the Pill Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles


8.2.1. F. Hoffmann-La Roche AG (Flatiron Health)
8.2.2. Otsuka Pharmaceuticals Co., Ltd
8.2.3. Amgen, Inc.
8.2.4. AstraZeneca Plc
8.2.5. Novartis AG
8.2.6. Sanofi S.A
8.2.7. Novo Nordisk A/S
8.2.8. Eli Lilly and Company
8.2.9. Johnson & Johnson
8.2.10. Teva Pharmaceutical Industries Ltd
8.2.11. Other Prominent Players

Segmentation of Beyond the Pill Market-

Beyond the Pill Market By Therapeutic Area:

  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Asthma
  • Others

Beyond the Pill Market

Beyond the Pill Market By Offerings:

  • Services
  • Monitoring
  • Assistance
  • Information
  • Education

Beyond the Pill Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Beyond the Pill Market?

Beyond the Pill Market expected to grow at 11.34% CAGR during the forecast period for 2023-2031

F. Hoffmann-La Roche AG (Flatiron Health), Otsuka Pharmaceuticals Co., Ltd., Amgen, Inc., AstraZeneca Plc., Novartis AG, Sanofi S.A., Novo Nordisk A/S

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach